- ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
- Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask
- ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
- ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024
- ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024
- ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference
- ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices
- ResMed Secures Significant Victory in Patent Fight Against New York University
- Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally
- ResMed Adopts New Operating Model to Accelerate Long-term Growth
More ▼
Key statistics
On Thursday, Resmed Inc (RMD:NYQ) closed at 198.03, -18.68% below its 52-week high of 243.52, set on Apr 28, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 197.14 |
---|---|
High | 198.54 |
Low | 196.47 |
Bid | 189.57 |
Offer | 200.00 |
Previous close | 196.33 |
Average volume | 1.09m |
---|---|
Shares outstanding | 147.09m |
Free float | 145.88m |
P/E (TTM) | 32.81 |
Market cap | 29.13bn USD |
EPS (TTM) | 6.04 USD |
Annual div (ADY) | 1.92 USD |
---|---|
Annual div yield (ADY) | 0.98% |
Div ex-date | Feb 07 2024 |
Div pay-date | Mar 14 2024 |
Data delayed at least 15 minutes, as of Mar 28 2024 20:10 BST.
More ▼